Global | English
简体中文
English
Home
Gene Therapy
Gene Editing Technology Innovation Platform
Hematopoietic Stem Cell Platform
Cell Therapy
Allogeneic Universal Cell Platform
Non-viral site-specific integration CAR-T platform
Enhanced T Cell Platform
In Vivo Gene Editing CAR-T Platform
News
Company News
About Us
About Us
Leadership
Our Culture
Contact Us
Contact Information
News
Company News
Published Paper
Company News
6-Year Follow-Up Confirms Durable Efficacy of BRL-101 in β‑Thalassemia
6-Year Follow-Up Confirms Durable Efficacy of BRL-101 in β‑Thalassemia
First β⁰/β⁰ transfusion-dependent β-thalassemia patient remains transfusion-independent for six years; all 30 patients in the pivotal Phase II trial have been dosed
2026-07-22
简体中文
English
Home
Gene Therapy
Gene Editing Technology Innovation Platform
Hematopoietic Stem Cell Platform
Cell Therapy
Allogeneic Universal Cell Platform
Non-viral site-specific integration CAR-T platform
Enhanced T Cell Platform
In Vivo Gene Editing CAR-T Platform
News
Company News
About Us
About Us
Leadership
Our Culture
Contact Us
Contact Information
Back to top
